Skip to main content

Table 1 Patient demographics and tumor characteristics by treatment arm

From: A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

 

Standard

(N = 16)

Experimental

(N = 14)

Total

(N = 30)

p value

Median age, years (range)

57.2 (39.6–74.9)

53.1 (27.8–69.7)

54.7 (27.8–74.9)

0.42

Race/ethnicity

   

0.71

 Caucasian

11 (68.8%)

7 (50.0%)

18 (60.0%)

 

 Hispanic

4 (25.0%)

5 (35.7%)

9 (30.0%)

 

 African American

0 (0.0%)

1 (7.1%)

1 (3.3%)

 

 Asian

1 (6.3%)

1 (7.1%)

2 (6.7%)

 

Tumor type

   

0.21

 Invasive ductal carcinoma

16 (100%)

12 (85.7%)

28 (93.3%)

 

 Invasive lobular carcinoma

0 (0.0%)

1 (7.1%)

1 (3.3%)

 

 Invasive mammary carcinoma

0 (0.0%)

1 (7.1%)

1 (3.3%)

 

Stage

   

0.72

 Stage II

7 (43.8%)

8 (57.1%)

15 (50.0%)

 

 Stage III

9 (56.3%)

6 (42.9%)

15 (50.0%)

 

Hormone status

    

 ER negative

8 (50%)

6 (43%)

14 (46.6%)

 

 ER positive

8 (50%)

8 (57.1%)

16 (53.3%)

 

Grade

   

0.27

 Grade 2

5 (31.3%)

8 (57.1%)

13 (43.3%)

 

 Grade 3

11 (68.8%)

6 (42.9%)

17 (56.7%)

 

 Ki-67

50.5 (2--80)

55.9 (15–80)

53.2 (15–80)

0.54